There is a reason that the anorexigenic gut hormones landed as the first question in my review book. This topic is not only high yield for the test but also the basis for many of the newer anti-obesity medications. In fact, it is the understanding of these gastrointestinal satiety hormones that led to the development of semaglutide and tirzepatide, the two most potent anti-obesity medications currently on the market. All gastrointestinal hormones we will discuss today have been synthetically produced and studied for their potential weight loss effects with many still in clinical trials.

Ghrelin, the potent gastrointestinal hunger hormone, requires multiple counteracting hormones to keep it in check. These counteracting meal-terminating, anorexigenic hormones allow us to feel full (satiety) and increase energy expenditure by stimulating the central anorexigenic pathway and inhibiting the orexigenic pathway. It still amazes me that we require multiple potent hormones to slow down the effects of ghrelin (ghrelin is discussed in another blog which can be viewed here). These other hormones and their high-yield points are discussed below:

Glucagon-like peptide 1 (GLP-1): This hormone is endogenously secreted by the L-cells of the small intestine and colon in response to nutrient ingestion, including carbohydrates, fats, and proteins. Pharmacologically, GLP-1 receptor agonists have demonstrated efficacy for type 2 diabetes and obesity, both as monotherapy and as components of dual-agonist therapies, such as tirzepatide (GLP-1/GIP), and investigational triple-agonist therapies, such as retatrutide (GLP-1/GIP/glucagon). GLP-1 receptor agonists were initially approved as injectable medications for type 2 diabetes and subsequently for obesity management. Oral semaglutide was previously approved for diabetes and, in December 2025, received FDA approval for chronic weight management, becoming available in January 2026. Semaglutide has also demonstrated cardiovascular benefits and is approved to reduce major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity. In 2025, injectable semaglutide received accelerated approval for noncirrhotic metabolic dysfunction–associated steatohepatitis (MASH) with moderate to advanced fibrosis (F2–F3). Finally, endogenous GLP-1 is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), and pharmacologic inhibitors of this enzyme (the “gliptins”) increase endogenous active GLP-1 levels.

Cholecystokinin (CCK): This hormone is secreted by the I-cells of the duodenum and jejunum primarily in response to dietary fat and protein ingestion. It slows gastric emptying, promotes satiation, and stimulates gallbladder contraction, releasing bile to facilitate fat digestion and absorption. Although studied as a potential pharmacotherapy for obesity, its clinical utility has been limited by factors including tachyphylaxis and gastrointestinal adverse effects.

Glucose-dependent insulinotropic peptide (GIP): This hormone is secreted by K-cells of the duodenum and jejunum in response to nutrient ingestion, including carbohydrates, fats, and proteins. It has an incretin effect, stimulating insulin secretion in a glucose-dependent manner. GIP can also stimulate glucagon secretion, particularly at lower glucose concentrations, and influences adipose tissue metabolism. Pharmacologically, GIP receptor agonism has demonstrated substantial weight-loss efficacy when combined with GLP-1 receptor agonism, as seen with tirzepatide. GIP receptor agonism is also being investigated in combination with glucagon receptor agonism, as demonstrated by the investigational triple agonist retatrutide.

Oxyntomodulin: This hormone is secreted by L-cells of the small intestine and colon following nutrient ingestion. It suppresses appetite and reduces food intake, with some studies suggesting an increase in energy expenditure. Unlike GLP-1, oxyntomodulin activates both GLP-1 and glucagon receptors, although its effects at these receptors are relatively weak. Native oxyntomodulin has limited therapeutic utility because of its short half-life and relatively modest potency. However, longer-acting analogs and dual GLP-1/glucagon receptor agonists are being investigated for obesity management.

Peptide YY (PYY): This hormone is secreted by L-cells of the distal small intestine and colon in response to nutrient ingestion, particularly dietary fat and protein. Although secreted predominantly from the distal intestine, it has effects throughout the gastrointestinal tract, including delayed gastric emptying and slowed intestinal transit, contributing to the ileal brake mechanism. PYY also suppresses appetite and promotes satiety. Pharmacologically, PYY-based therapies have demonstrated appetite-suppressing effects, although nausea and vomiting have limited their tolerability and clinical development. Longer-acting formulations and combination therapies, including those involving oxyntomodulin, continue to be investigated for obesity management.

In addition to knowing what action these hormones do, it is important to know where (i.e., duodenum, jejunum, colon, etc.) these hormones are produced and what specific cells secrete them (i.e., I, K, L cells), which is summarized in the table below. There are a number of approaches these hormones can be tested. For example, if a patient just completed a meal, which hormone is decreased? You can expect to see central hormones intermingled. And vice versa, if a patient is fasting just prior to their first meal, which hormone is likely to be increased or decreased? Know these hormones inside and out, as they are the bread and butter of obesity medicine.

Sample Question:

A 41-year-old man is seen in the hospital on postoperative day one after Roux-en-Y gastric bypass. Home medications include glargine 30 units nightly and aspart sliding scale with meals. Since surgery, he has not required any insulin to maintain normal glucose levels and has plans to be discharged on a low dose of immediate-release metformin. The increased endogenous hormone responsible for this diabetes medication adjustment

A. is only secreted in the small intestine

B. is secreted in response to fat and protein ingestion

C. reduces hepatic gluconeogenesis

D. has the same quantitative effects as seen after sleeve gastrectomy

E. causes gallbladder contraction

 

Next Week: Aspire Assist® device

Upcoming: Body fat measurements (calipers vs. DXA, etc), and Pradar-Willi vs. Angelman.

For more practice questions, check out the following:

  • Obesity Medicine Board Review Questions (2026): Qs 1, 24, 29, and 260.
  • Obesity Medicine Practice Tests (2026): Qs 37, 71, 84, 122, 156, and 231.

(Copyright 2026) Obesity Medicine Board Review Questions, LLC: obesitymedicinereview.com

Featured image: Modified from VectorStock (image license purchased)

Copyediting by Kelly Smith